Biotest AG (Biotest AG) Debt-to-Asset : 0.00 (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Biotest AG Debt-to-Asset?

Biotest AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.0 Mil. Biotest AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.0 Mil. Biotest AG's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $1,572.6 Mil. Biotest AG's debt to asset for the quarter that ended in Mar. 2024 was 0.00.

Biotest AG Debt-to-Asset Historical Data

The historical data trend for Biotest AG's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotest AG Debt-to-Asset Chart

Biotest AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.37

0.41

0.45

0.48

0.44

Biotest AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															-	-	-	0.44	-

Competitive Comparison of Biotest AG's Debt-to-Asset

For the Biotechnology subindustry, Biotest AG's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biotest AG's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotest AG's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Biotest AG's Debt-to-Asset falls into.

Biotest AG Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Biotest AG's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(253.217	+	416.467)	/	1538.604
	=	0.44

Biotest AG's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	1572.609
	=	0.00

Biotest AG (OTCPK:BIESF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Biotest AG Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Biotest AG's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Biotest AG (Biotest AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotest AG (OTCPK:BIESF) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

BIO3:Germany BIO3:Austria

Address

Landsteinerstrasse 5, Dreieich, DEU, 63303

Website

https://www.biotest.com

Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The operating business segments are Therapy, Plasma and Services, and Other segments. It generates maximum revenue from the Therapy segment. Geographically, it derives a majority of revenue from Central Europe and also has a presence in other countries.